Core Viewpoint - As of January 14, 2026, the stock price of Kangtong Medical (301515) closed at 26.15 yuan, down 1.88%, with a turnover rate of 15.84% and a trading volume of 103,900 hands, amounting to a total transaction value of 273 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Kangtong Medical reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06% [3] - The net profit attributable to the parent company was -10.21 million yuan, a year-on-year decline of 150.92% [3] - The net profit excluding non-recurring items was -12.87 million yuan, down 176.82% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main revenue of 79.12 million yuan, an increase of 42.81% year-on-year [3] - The single-quarter net profit attributable to the parent company was -1.80 million yuan, a year-on-year decrease of 138.94% [3] - The single-quarter net profit excluding non-recurring items was -2.60 million yuan, down 182.34% year-on-year [3] - The company's debt ratio stood at 40.94%, with an investment income of -179,400 yuan and financial expenses of 542,400 yuan, while the gross profit margin was 22.45% [3] Group 2: Capital Flow - On January 14, 2026, the net inflow of main funds was 6.57 million yuan, accounting for 2.4% of the total transaction value, while retail investors saw a net inflow of 4.18 million yuan, making up 1.53% of the total [1] - Over the past five days, the financing buy amounted to 35.98 million yuan, with financing repayment at 25.90 million yuan, resulting in a net financing increase of 10.08 million yuan, totaling 41.15 million yuan over three consecutive days [2] - The margin trading data indicated no shares were sold or repaid, with a margin balance of 9.77 million yuan [2]
港通医疗（301515）1月14日主力资金净买入656.90万元